Teva reports first quarter 2024 financial results and reaffirms 2024 financial outlook

Tel aviv, israel--(business wire)--teva pharmaceutical industries ltd. (nyse and tase: teva) today reported results for the quarter ended march 31, 2024. mr. richard francis, teva's president and ceo, said, "in 2024 teva is off to a good start, with global revenues of $3.8 billion showing growth of 5% in local currency terms compared to q1 2023, fueled by robust growth in our generics business across all regions, and continued growth of our innovative brands austedo and ajovy." mr. francis cont.
TEVA Ratings Summary
TEVA Quant Ranking